Enhancement of rat liver uridine kinase activity by various metabolic inhibitors.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001374:Azacitidine / Q000494:pharmacology; D001380:Azauridine / Q000378:metabolism; D002250:Carbon Radioisotopes; D002474:Cell-Free System; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology; D004032:Diet; D004317:Doxorubicin / Q000494:pharmacology; D066298:In Vitro Techniques; D008099:Liver / Q000166:cytology / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D009963:Orotic Acid / Q000378:metabolism; D010770:Phosphotransferases / Q000378:metabolism*; D011691:Puromycin / Q000494:pharmacology; D011743:Pyrimidines / Q000138:chemical synthesis; D051381:Rats; D013268:Stimulation, Chemical; D013853:Thioacetamide / Q000494:pharmacology; D013950:Thymus Gland / Q000201:enzymology; D014529:Uridine
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D011743:Pyrimidines; D013853:Thioacetamide; D003609:Dactinomycin; D011691:Puromycin; D009963:Orotic Acid; D001380:Azauridine; D004317:Doxorubicin; D003513:Cycloheximide; D010770:Phosphotransferases; D001374:Azacitidine; D014529:Uridine; D003630:Daunorubicin